JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Ocular Therapeutix Inc

Closed

SectorHealthcare

12.19 2.52

Overview

Share price change

24h

Current

Min

12.14

Max

12.24

Key metrics

By Trading Economics

Income

-16M

-64M

Sales

-6.4M

11M

Profit margin

-602.342

Employees

274

EBITDA

-20M

-64M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+42.83% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

510M

1.8B

Previous open

9.67

Previous close

12.19

News Sentiment

By Acuity

50%

50%

145 / 375 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Ocular Therapeutix Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jul 2025, 17:53 UTC

Major Market Movers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 Jul 2025, 15:58 UTC

Earnings
Major Market Movers

Aon Shares Rise After 2Q Earnings Beat

25 Jul 2025, 15:08 UTC

Major Market Movers

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 Jul 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 Jul 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 Jul 2025, 20:40 UTC

Earnings

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 Jul 2025, 20:10 UTC

Earnings

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 19:56 UTC

Earnings

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 Jul 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 Jul 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 Jul 2025, 19:01 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 Jul 2025, 17:38 UTC

Major Market Movers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 Jul 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25 Jul 2025, 17:13 UTC

Earnings

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 Jul 2025, 16:46 UTC

Earnings

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 Jul 2025, 16:45 UTC

Earnings

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 Jul 2025, 16:27 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 Jul 2025, 16:02 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 Jul 2025, 15:34 UTC

Earnings

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 Jul 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 Jul 2025, 15:05 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 Jul 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 Jul 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 Jul 2025, 14:36 UTC

Market Talk
Earnings

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer Comparison

Price change

Ocular Therapeutix Inc Forecast

Price Target

By TipRanks

42.83% upside

12 Months Forecast

Average 17.44 USD  42.83%

High 22 USD

Low 14 USD

Based on 10 Wall Street analysts offering 12 month price targets forOcular Therapeutix Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

6.97 / 7.62Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

145 / 375 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.